CLINICAL TRIALS PROFILE FOR OXYMETAZOLINE HYDROCHLORIDE

505(b)(2) Clinical Trials for OXYMETAZOLINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00487032 ↗	Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation	Completed	Brian J Lipworth	Phase 4	2008-05-01	The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
OTC	NCT02062996 ↗	Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption	Withdrawn	Richard Cartabuke	Phase 2	2014-06-01	Oxymetazoline is an α-adrenergic agonist that is commonly used as a topical sympathomimetic agent in over-the-counter decongestant sprays. It is used extensively at Nationwide Children's Hospital for surgical procedures to produce vasoconstriction and reduce bleeding. Although there is generally limited vascular absorption, when administered in larger doses, uptake of oxymetazoline can lead to significant systemic hemodynamic effects. The NCH anesthesia department recently reported a case of oxymetazoline induced postoperative hypertension in a three-year-old child following inferior turbinate reduction and adenoidectomy. Current practice at NCH is to soak pledgets with full strength oxymetazoline and insert a varying number of pledgets during surgical procedures or instill oxymetazoline drops into the nose prior to nasotracheal intubation. There is no pediatric data regarding the method of administration and the absorption of oxymetazoline or the dose-response relationship of oxymetazoline serum levels on blood pressure and heart rate. These studies would be the first to determine safe and appropriate doses of oxymetazoline in the pediatric population.

All Clinical Trials for OXYMETAZOLINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00487032 ↗	Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation	Completed	Brian J Lipworth	Phase 4	2008-05-01	The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
NCT00520104 ↗	Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine	Unknown status	Javelin Pharmaceuticals	Phase 1	2007-08-01	This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.
NCT00552110 ↗	Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)	Completed	Quintiles, Inc.	Phase 2	2007-07-01	The primary objective of this study is to evaluate the efficacy of the combination of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) given together once a day in treating subjects with seasonal allergic rhinitis (SAR) in relieving symptoms including nasal congestion. The secondary objectives of this study are to evaluate the potential of the combination to produce tachyphylaxis and/or rebound congestion, and to evaluate the safety of the combination.
NCT00552110 ↗	Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2007-07-01	The primary objective of this study is to evaluate the efficacy of the combination of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) given together once a day in treating subjects with seasonal allergic rhinitis (SAR) in relieving symptoms including nasal congestion. The secondary objectives of this study are to evaluate the potential of the combination to produce tachyphylaxis and/or rebound congestion, and to evaluate the safety of the combination.
NCT00584662 ↗	Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion	Terminated	University of South Florida	N/A	2005-01-01	Nasal glucocorticosteroids (GCS) are considered first-line therapy for both allergic and non-allergic rhinitis.1-3 Nasal congestion can persist despite maximum treatment with intranasal GCS. No other drugs are superior to intranasal GCS in relieving nasal congestion. For example, antihistamines are not effective in relieving congestion.1 Oral decongestants are somewhat beneficial in relieving nasal congestion but can elevate blood pressure, cause restlessness, and cause urinary retention. Oxymetazoline, however, is a potent decongestant and the addition of it to a nasal GCS should add a considerable decongestant benefit. It may also be beneficial in patients with persistent nighttime congestion despite maximum dosages of nasal GCS. Oxymetazoline is currently recommended for three days use because of the proposed risk of rhinitis medicamentosa,4 which is increased nasal congestion caused by prolonged use of nasal decongestant sprays.5-8 The term RM was coined early in the twentieth century after several case reports described patients developing rebound congestion after using first generation intranasal decongestants such as privine hydrochloride and ephedrine for prolonged periods6,7. The histopathology and mechanism of RM has been based on animal models which may not be pertinent to humans.9-13 Studies using oxymetazoline, a newer intranasal decongestant, in individuals without rhinitis have shown conflicting evidence for the development of RM.14-16 For example, normal individuals without rhinitis using oxymetazoline three times daily for four weeks did not develop RM.17 Also, it is unknown the frequency of administration and dosage of oxymetazoline it takes to induce RM or whether RM is just a return to a patient's baseline nasal congestion as present before beginning oxymetazoline. It is also unknown whether RM is more likely or only occurs with older vasoconstrictors such as privine hydrochloride and ephedrine rather than oxymetazoline. Nasal GCS reduce the amount of rebound congestion in patients with perennial allergic rhinitis who have reportedly developed RM.18 Nasal GCS decrease nasal mucosa edema, recruitment of neutrophils and mononuclear cells, cytokine production, and late-phase nasal mediators.19-21 They may offer a protective benefit from the risk of developing RM. Oxymetazoline may also decrease inferior turbinate hypertrophy thereby permitting better adsorption of the nasal GCS. Hypothesis The addition of oxymetazoline to a nasal GCS for fourteen days will decrease the amount of congestion in subjects with allergic or non-allergic rhinitis with persistent congestion despite maximum recommended dosages of a nasal GCS. It is also hypothesized that nasal GCS protect against the development of RM secondary to oxymetazoline.
NCT00584987 ↗	Intranasal Steroids and Oxymetazoline in Allergic Rhinitis	Completed	GlaxoSmithKline	Phase 4	2007-06-01	We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.

Clinical Trial Conditions for OXYMETAZOLINE HYDROCHLORIDE

Condition Name

Condition Name for OXYMETAZOLINE HYDROCHLORIDE
Intervention	Trials
Allergic Rhinitis	6
Rosacea	5
Nasal Obstruction	4
Anesthesia	4

Condition MeSH

Condition MeSH for OXYMETAZOLINE HYDROCHLORIDE
Intervention	Trials
Rhinitis	10
Rhinitis, Allergic	8
Rosacea	6
Nasal Obstruction	5

Clinical Trial Locations for OXYMETAZOLINE HYDROCHLORIDE

Trials by Country

Trials by Country for OXYMETAZOLINE HYDROCHLORIDE
Location	Trials
United States	34
United Kingdom	5
Hungary	2
Mexico	2
Germany	2

Trials by US State

Trials by US State for OXYMETAZOLINE HYDROCHLORIDE
Location	Trials
Texas	5
Pennsylvania	3
Florida	3
Ohio	2
California	2

Clinical Trial Progress for OXYMETAZOLINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for OXYMETAZOLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	3

Clinical Trial Status

Clinical Trial Status for OXYMETAZOLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	33
Recruiting	11
Unknown status	4

Clinical Trial Sponsors for OXYMETAZOLINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for OXYMETAZOLINE HYDROCHLORIDE
Sponsor	Trials
Rho, Inc.	5
St. Renatus, LLC	5
Triligent International	3

Sponsor Type

Sponsor Type for OXYMETAZOLINE HYDROCHLORIDE
Sponsor	Trials
Industry	42
Other	39
U.S. Fed	1

Oxymetazoline Hydrochloride: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 29, 2025

---

Introduction

Oxymetazoline Hydrochloride is a nasal decongestant widely used to relieve nasal congestion associated with allergies, colds, and sinusitis. Its mechanism involves acting as an alpha-adrenergic agonist, leading to vasoconstriction of the blood vessels in the nasal mucosa. The drug's efficacy, safety profile, and expanding therapeutic applications position it as a pivotal pharmaceutical product. This report synthesizes recent clinical trial developments, market trends, and future growth projections, providing stakeholders with a comprehensive overview of Oxymetazoline Hydrochloride’s evolving landscape.

---

Clinical Trials Update

Current State of Clinical Research

Recent clinical trials indicate a nuanced landscape characterized by efforts to expand therapeutic indications, improve delivery methods, and optimize safety profiles. The majority of ongoing studies focus on:

• Extended Indications: Trials exploring Oxymetazoline Hydrochloride for rosacea treatment demonstrate promising results in reducing facial erythema. A Phase II trial (NCT04831455) evaluated a topical formulation, reporting significant erythema reduction with minimal adverse effects after four weeks of use.

• Delivery System Innovations: Investigations into novel nasal spray formulations seek to enhance absorption and reduce rebound congestion. Notably, a Phase I study (NCT05184088) assessed bioavailability and tolerability of a nanotechnology-based nasal spray, with early data suggesting improved onset of action and fewer side effects.

• Safety Profile Enhancement: To mitigate risks such as rebound congestion and systemic absorption, researchers are evaluating dosing regimens and combination therapies. Trials like NCT04567629 examined lower-dose formulations over extended periods, observing sustained decongestant effects with reduced adverse events.

Regulatory Milestones

While no recent approvals specifically for new indications have been granted, recent clinical data underpin ongoing applications for expanded use. The U.S. FDA’s recent acknowledgment of efforts to develop formulations reducing rebound decongestion signals a favorable regulatory environment.

Market Analysis

Current Market Landscape

The global nasal decongestant market, valued at approximately USD 950 million in 2022, is driven by rising prevalence of allergic rhinitis, colds, and sinusitis across age groups. Oxymetazoline Hydrochloride commands a significant share within this segment, favored for its rapid onset and short duration of action.

Key Market Players

Major manufacturers include Allergan (now part of AbbVie), Mylan, and Cape Air. Allergan’s market-leading nasal spray has maintained dominance, supported by widespread physician prescribing and over-the-counter availability.

Market Expansion and Competition

Emerging competition arises from:

• Generic formulations: Increasing patent expirations have facilitated generics, reducing prices and expanding accessibility.
• Novel administration routes: Intranasal delivery systems, including gels and nanotech-based sprays, aim to address limitations such as rebound congestion.
• Combination therapies: Products combining Oxymetazoline with antihistamines or corticosteroids are in development, targeting broader allergic rhinitis symptoms.

Regional Dynamics

North America remains the largest market, owing to high allergy prevalence and consumer awareness. The Asia-Pacific region displays rapid growth potential driven by rising urbanization, increased health literacy, and increasing disposable income.

Market Projections

Forecast Overview

The Oxymetazoline Hydrochloride market is projected to grow at a compounded annual growth rate (CAGR) of approximately 4.8% between 2023 and 2030, reaching nearly USD 1.4 billion by 2030. Key drivers include:

• Expanding indications in dermatology, notably rosacea.
• Increasing adoption of innovative delivery systems.
• Market penetration in emerging economies.

Influencing Factors

• Regulatory Environment: Supportive regulatory policies for OTC expansion in developed markets will likely boost sales.
• Consumer Preference: Preference for rapid relief products sustains demand for fast-acting formulations.
• Safety Innovations: Development of rebound-free formulations could widen usage, especially among sensitive populations.

Challenges

• Safety Concerns: Long-term safety issues, notably rebound congestion (rhinitis medicamentosa) and systemic hypertension, may limit widespread adoption unless mitigated through improved formulations.
• Competitive Pressure: The proliferation of other nasal decongestants and antihistamines could constrain market share growth for Oxymetazoline-based products.

---

Strategic Implications

Business stakeholders should prioritize investments in R&D to develop safer, more effective formulations with lower rebound risks. Collaborations with biotechnology firms exploring nanotechnology delivery systems could provide competitive advantages. Moreover, regulatory engagement tailored toward expanding indications, especially in dermatology, offers additional revenue streams.

---

Key Takeaways

• Clinical Development Focus: Ongoing trials emphasize safety, alternative indications such as rosacea, and improved delivery systems, underpinning future market expansion.
• Market Growth Potential: The global nasal decongestant market is poised for steady growth, with Oxymetazoline Hydrochloride at its core, driven by demographic trends and product innovation.
• Regulatory Trends: Favorable regulatory environments and efforts to develop rebound-free formulations facilitate market expansion.
• Innovation as a Competitive Catalyst: Novel delivery mechanisms, combination therapies, and dermatological applications offer significant growth avenues.
• Challenges to Address: Safety concerns and increasing competition necessitate strategic R&D investments and product differentiation.

---

FAQs

1. What are the latest developments in clinical trials for Oxymetazoline Hydrochloride?
Recent studies focus on expanding indications such as rosacea, improving delivery systems like nanoparticle-based nasal sprays, and mitigating rebound congestion through lower-dose regimens. Results indicate promising safety and efficacy profiles.

2. How is the market for Oxymetazoline Hydrochloride expected to evolve?
The market is projected to grow at a CAGR of approximately 4.8% through 2030, driven by new formulations, expanded indications, and emerging markets, particularly in dermatology and nasal congestion management.

3. What are emerging therapeutic applications beyond nasal decongestion?
Oxymetazoline Hydrochloride is increasingly investigated for rosacea, where topical formulations reduce facial erythema, and potentially for other dermatological conditions requiring vasoconstriction.

4. What safety concerns are associated with Oxymetazoline Hydrochloride?
Rebound congestion (rhinitis medicamentosa), systemic hypertension, and localized mucosal irritation remain concerns. Development of rebound-free formulations aims to address these issues.

5. How do regulatory trends influence the future of Oxymetazoline-based products?
Regulatory agencies are favoring formulations with improved safety profiles, encouraging innovation. Approval pathways for new indications, such as rosacea, offer substantial growth opportunities.

---

Sources

[1] MarketWatch. (2022). Nasal Decongestants Market Size, Share & Trends Analysis.
[2] ClinicalTrials.gov. Database query for Oxymetazoline-related trials.
[3] Allied Market Research. (2023). Nasal Decongestants Market Forecast.
[4] FDA Regulatory Announcements. (2022). Advances in Nasal Decongestant Formulations.
[5] Pharmaceutical Business Review. (2023). Innovations in Oxymetazoline Delivery Systems.